Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT00619424
- Locations
- 🇮🇹
GSK Investigational Site, Orbassano (TO), Piemonte, Italy
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 212
- Registration Number
- NCT00620269
- Locations
- 🇰🇷
National Cancer Center, Korea, Goyang-si, Gyenggi-do, Korea, Republic of
Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 50
- Registration Number
- NCT00615758
- Locations
- 🇬🇷
IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece
🇬🇷401 Military Hospital, Medical Oncology Unit, Athens, Greece
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00614653
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2011-08-22
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 29
- Registration Number
- NCT00611468
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT00609804
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 201
- Registration Number
- NCT00606502
- Locations
- 🇺🇸
Donald Berdeaux, Great Falls, Montana, United States
🇦🇷Instituto Medico Especializado Alexander Fleming, Buenos Aires, Cuidad De Buenos Aires, Argentina
🇦🇷Policlinica Privada - Instituto de Medicina Nuclear, Bahia Blanca, Provincia De Buenos Aires, Argentina
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT00603915
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 141
- Registration Number
- NCT00602030
- Locations
- 🇺🇸
Fairfax Northern Virginia Hematology-Oncology, Fairfax, Virginia, United States
🇺🇸HOPE (Hematology Oncology Physicians & Extenders), Tucson, Arizona, United States
🇺🇸Oncology Associates of Oregon, Eugene, Oregon, United States
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00600496
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.